Follistatin Biomarker for Early Type 2 Diabetes Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing type 2 diabetes risk are inadequate as they often detect abnormal glucose levels too late, failing to identify individuals at different risk levels for developing diabetes, and rely solely on glucose measurements, which is not sufficient for early detection and prevention.
Innovation Solution
A novel method using follistatin as a biomarker in combination with HbA1c, proinsulin, and C-peptide to predict short-term high-risk development of type 2 diabetes through k-means clustering and recursive feature elimination, allowing for early identification and preventive treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If conventional glucose measurement methods are used for diabetes risk assessment, then the detection process is simple and inexpensive, but the detection timing is too late to enable effective prevention
Solution Approach 1:
The patent applies preliminary action by measuring follistatin levels before diabetes onset to enable early risk stratification. The method identifies individuals at high risk of developing type 2 diabetes within the next 4 years by detecting elevated follistatin levels in combination with HbA1c, allowing preventive interventions to be initiated before disease manifestation occurs.
Solution Approach 2:
The patent employs a composite biomarker panel combining follistatin with traditional diabetes markers (HbA1c, proinsulin, C-peptide) to create a multi-dimensional risk assessment tool. This composite approach integrates multiple biological signals to achieve both early detection capability and high predictive accuracy, resolving the contradiction between timing and precision.
2Loss of information
If only glucose measurements are used for diabetes assessment, then the testing protocol is simple, but the ability to identify individuals at different risk levels is insufficient
Solution Approach 1:
The patent applies segmentation by dividing the population into distinct risk strata (high, intermediate, low risk) based on follistatin levels combined with HbA1c. This segmentation enables targeted prevention strategies for different risk groups, providing granular risk information that glucose measurements alone cannot deliver.
Solution Approach 2:
The follistatin biomarker serves multiple functions: it enables early risk detection, stratifies individuals into different risk categories, and predicts short-term diabetes development. This multi-functionality allows a single additional test to provide comprehensive risk assessment information without requiring multiple specialized tests.
3Measurement precision
If follistatin is added to the biomarker panel for early prediction, then the accuracy of diabetes risk prediction improves, but the complexity of the testing method increases
Solution Approach 1:
The patent merges follistatin measurement with existing diabetes screening markers (HbA1c, proinsulin, C-peptide) into a unified risk prediction model. By combining these biomarkers in a multi-marker panel analyzed through machine learning algorithms, the system achieves high predictive accuracy while leveraging established testing infrastructure.
Data Source
Figure 1A~1B
Figure 2A~2E
Figure 3A
AI summary
With the present disclosure there is detailed use of follistatin as a biomarker for early diagnosis and/or prediction of type 2 diabetes, liver follistatin secretion regulated by GCKR, which use is herein reported. Further, a method of composing a biomarker signature for the early prediction of type 2 diabetes in a human is herein disclosed.